SEARCH

SEARCH BY CITATION

References

  • 1
    Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997;99:S781S786.
  • 2
    Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;5(Suppl):S147S334.
  • 3
    Pawankar R. Allergic rhinitis and asthma: are they manifestations of one syndrome? Clin Exp Allergy 2006;36:14.
  • 4
    Beasley R, Crane J, Lai CK, Pearce N. Prevalence and etiology of asthma. J Allergy Clin Immunol 2000;105:S466S472.
  • 5
    Linneberg A, Nielsen NH, Madsen F, Frolund L, Dirksen A, Jorgensen T. Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart: the Copenhagen Allergy Study. J Allergy Clin Immunol 2000;106:247252.
  • 6
    Muldoon MF, Barger SD, Flory JD, Manuck SB. What are quality of life measurements measuring? BMJ 1998;316:542545.
  • 7
    Jones PW. Quality of life measurement in asthma. Eur Respir J 1995;8:885887.
  • 8
    Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:7783.
  • 9
    Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 1999;104:364369.
  • 10
    Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994;94:182188.
  • 11
    Bousquet PJ, Combescure C, Neukirch F, Klossek JM, Mechin H, Daures JP et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 2007;62:367372.
  • 12
    Leong KP, Yeak SC, Saurajen AS, Mok PK, Earnest A, Siow JK et al. Why generic and disease-specific quality-of-life instruments should be used together for the evaluation of patients with persistent allergic rhinitis. Clin Exp Allergy 2005;35:288298.
  • 13
    Terreehorst I, Duivenvoorden HJ, Tempels-Pavlica Z, Oosting AJ, De Monchy JG, Bruijnzeel-Koomen CA et al. Comparison of a generic and a rhinitis-specific quality-of-life (QOL) instrument in patients with house dust mite allergy: relationship between the SF-36 and Rhinitis QOL Questionnaire. Clin Exp Allergy 2004;34:16731677.
  • 14
    Juniper EF, Thompson AK, Roberts JN. Can the standard gamble and rating scale be used to measure quality of life in rhinoconjunctivitis? Comparison with the RQLQ and SF-36 Allergy 2002;57:201206.
  • 15
    Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001;33:328336.
  • 16
    Drummond MF, Sculpher MJ, Torrance GW, O’Brien B, Stoeckmann E. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford: Medical Publications, 2005.
  • 17
    Graham DM, Blaiss MS. Quality-of-life outcomes measures of asthma and allergic rhinitis. Pediatr Ann 2000;29:438443.
  • 18
    Brazier J. The SF-36 health survey questionnaire – a tool for economists. Health Econ 1993;2:213215.
  • 19
    The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199208.
  • 20
    Crown WH, Olufade A, Smith MW, Nathan R. Seasonal versus perennial allergic rhinitis: drug and medical resource use patterns. Value Health 2003;6:448456.
  • 21
    Berggren F, Hjelmgren J, Lindgren B. Differences in health care utilisation and workdays lost between individuals with and without asthma. Appl Health Econ Health Policy 2003;2:165170.
  • 22
    Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:13221326.
  • 23
    Bachert C, Van Cauwenberge P. The WHO ARIA (allergic rhinitis and its impact on asthma) initiative. Chem Immunol Allergy 2003;82:119126.
  • 24
    Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000;30(Suppl. 1):25.
  • 25
    Bousquet J, Clark TJ, Hurd S, Khaltaev N, Lenfant C, O’byrne P et al. GINA guidelines on asthma and beyond. Allergy 2007;62:102112.
  • 26
    Sintonen H, Walker SR, Rosser R. Quality of life assessment. Key issues in the 1990s. Dordrecht: Kluwer Academic, 1992.
  • 27
    Sintonen H. The 15-D measure of health related quality of life I: reliability, validity and sensitivity of its healthstate descriptive system. Melbourne: NCHPE, 1994. Report no. 41.
  • 28
    Sintonen H. The 15-D measure of health related quality of life II. Feasibility, reliability and validity of its valuation system. Melbourne: NCHPE, 1995. Report no. 42.
  • 29
    Wittrup-Jensen KU, Pedersen KM Modelling weights for 15D. Paper presented at the 22nd Nordic Study Group Meeting in Odense, 22–25 August. PhD Thesis; Faculty of Social Science, University of Southern Denmark, 2001.
  • 30
    Pedersen KM, Wittrup-Jensen K, Brooks R, Guidex C. Værdisætning af sundhed. Teorien om kvalitetsjusterede leveår og en dansk anvendelse (In Danish: valuation of health theory of quality adjusted life years). Odense: University of Southern Denmark, 2003.
  • 31
    Le CT, Boen JR. Health and number: basic biostatistical methods. New York: Wiley-Liss, 1995.
  • 32
    Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1997.
  • 33
    Bousquet J, Lund VJ, Van CP, Bremard-Oury C, Mounedji N, Stevens MT et al. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy 2003;58:733741.
  • 34
    Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838844.